Alternate Thursdays, noon - 1 p.m.
This 16-session ECHO series will cover the screening, diagnosis, and treatment of:
We will select clinical teams to participate based on interest, geographic distribution throughout Oregon, and ability to commit to the sessions. Clinical teams will include at least one prescribing clinician (MD, DO, PA, NP) and up to two other supporting staff that are in a position to develop new systems and processes to support care delivery. Other supporting staff could include a practice manager, quality improvement manager, behavioral health clinician, nurse care manager, pharmacist, or medical assistant.
*Accreditation: Oregon Health & Science University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit: OHSU School of Medicine designates this live activity for a maximum of 16.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|1 - Introduction||9/16/2021|
|2 - Basic Epidemiology of HCV||9/30/2021|
|3 - Treatment Program Overview||10/14/2021|
|4 - Special considerations in the diagnosis of HCV||10/28/2021|
|5 - Assessing Fibrosis of the liver||11/11/2021|
|6 - Basics of treatment with DAA’s (HCV Guidelines)||12/2/2021|
|7 - HCV treatment in PWUDs||12/16/2021|
|8 - HCV treatment in special populations||1/13/2022|
|9 - Natural History of Cirrhosis and its complications||1/27/2022|
|10 - Alternatives to provider-driven treatment||2/10/2022|
|11 - Hepatitis B infection||2/24/2022|
|12 - Harm Reduction||3/10/2022|
|13 - Treatment of Opioid, Methamphetamine and Alcohol Use Disorder||3/24/2022|
|14 - Real-Life Example of a HCV treatment clinic||4/7/2022|
|15 - Hepatocellular Carcinoma||4/21/2022|
|16 - When to Refer for Liver Transplant||5/5/2022|